Abstract: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (12) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

Abstract: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (30) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

Abstract: Sterilization method using plasma for sterilizing objects, wherein it is provided to introduce the objects to be sterilized into a sterilization chamber (13) and covey toward the latter a flow of air coming from a feed pipe (17) on which a plasma generator device (12) is disposed able to generate one or more gaseous compounds comprising a mixture of reactive oxygen species (ROS) and of reactive nitrogen species (RNS) so that the air is the carrier fluid which conveys the gaseous compounds toward the sterilization chamber (13); the method also provides to control the electric power used to produce the plasma as a function of the composition and/or the quantity of reactive species present in the sterilization chamber (13).

Abstract: The present invention relates to a method for selectively enhancing the production of factors A.sub.2 and/or A.sub.3 of antibiotic A/16686 either to isolate these single components or to enrich the complex in one or both the above components, which comprises adding an appropriate precursor of the desired antibiotic factor to an A/16686 producing culture during fermentation.

Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.

Abstract: Predominantly water based adhesive compositions and primers comprising:A) 2 to 50 parts by weight of a solution in a non-ionic surface active agent of one or more chlorinated polyolefins;B) 50 to 98 parts by weight of a component selected from:1) an aqueous dispersion comprising from 35 to 65 part per hundred by weight of vinylacetate-ethylene copolymer and2) an aqueous solution comprising from 0.1 to 5% by weight of an anionic surface-active agent.

Abstract: The object of this invention are de-mannosylated teicoplanin derivatives which can be obtained in good yield by microbiological transformation with cultures of Nocardia orientalis NRRL 2450 or Streptomyces candidus NRRL 3218.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: The present invention relates to new teicoplanin-like antibiotics differing from the parent compound in the length of the acyl group.The compounds of the invention are obtained according to a microbiological process and possess an antimicrobiol activity mainly against gram positive bacteria.

Abstract: The oject of this invention are de-mannosylated teicoplanin derivatives which can be obtained in good yield by microbiological transformation with cultures of Nocardia orientalis NRRL 2450 or Streptomyces candiodus NRRL 3218.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: Soft and low-density foam materials, obtained by means of an extrusion expansion (with physical blowing agents) of particular copolymers of ethylene with vinylacetate (and/or with alkyl esters of acrylic or methacrylic acid), are found to be very suitable for the manufacture of expanded articles with little shrinkage after expansion, free from creases on the surface or cracks on the cell walls, and having excellent characteristics, higher compressive strength and so on.

Abstract: Soft and low-density foam materials, obtained by means of an extrusion expansion (with physical blowing agents) of particular copolymers of ethylene with vinylacetate (and/or with alkyl esters of acrylic or methacrylic acid), are found to be very suitable for the manufacture of expanded articles with little shrinkage after expansion, free from creases on the surface or cracks on the cell walls, and having excellent characteristics, higher compressive strength and so on.

Abstract: The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Abstract: The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity expecially against gram-positive bacteria.

Abstract: The present invention is directed to a new antibiotic substance arbitrarily denominated antibiotic L 17046. This antibiotic substance is obtained from the known antibiotic substance called teicoplanin (formerly teichomycin) by chemical treatment. The new compound possesses antimicrobial activity especially against gram-positive bacteria.

Abstract: The present invention is directed to the essentially pure preparation of an antibiotic substance arbitrarily designated antibiotic L 17054. This antibiotic substance is obtained from the known antibiotic substance named teicoplanin (formerly teichomycin) by chemical treatment. The new compound and the pharmaceutically acceptable salts possess antimicrobial activity.

Abstract: The invention refers to an individual antibiotic substance selected from the group consisting of Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 in substantially pure form, and to the method of producing them by recovery from Teichomycin A.sub.2, a known antibiotic substance, by means of high-efficiency chromatographic methods. The single pure Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 are biologically distinguishable from Teichomycin A.sub.2 in that they have a higher degree of antibiotic activity against susceptible microorganisms.

Abstract: A new antibiotic, designated S/433, is disclosed which is produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces. This new antibiotic is active against gram-positive and gram-negative bacteria and is also active in inhibiting the growth of transplanted tumors.